Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals develops medicines for rare genetic and skin disorders. Its main approved drug is Scenesse, which helps patients with erythropoietic protoporphyria (a rare inherited condition that makes skin severely sensitive to sunlight) by protecting them from sun damage. The company is also working on treatments for other conditions like vitiligo, a skin disorder that causes loss of color, and various hormonal and neurological disorders. Clinuvel is based in Australia and sells its products internationally.